Matthias A Fante
Overview
Explore the profile of Matthias A Fante including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heidenreich S, Egger-Heidrich K, Halter J, Jost L, Stolzel F, Perl M, et al.
Bone Marrow Transplant
. 2025 Jan;
PMID: 39809902
Belumosudil is a first in class ROCK2-inhibitor approved by the FDA for the 3rd line treatment of chronic graft-versus-host disease (cGvHD). In this retrospective real-world analysis, we report safety and...
2.
Staudt S, Nikolka F, Perl M, Franz J, Leblay N, Leblay N, et al.
bioRxiv
. 2024 Sep;
PMID: 39314273
The microbiome is a complex host factor and key determinant of the outcome of antibody-based and cellular immunotherapy. Its postbiotics are a blend of soluble commensal byproducts that are released...
3.
Perl M, Herfeld K, Harrer D, Hopting M, Schweiger M, Sterz U, et al.
Haematologica
. 2024 Mar;
109(9):2969-2977.
PMID: 38546698
Chimeric antigen receptor (CAR) T-cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that has up to now been considered the result...
4.
Doering J, Perl M, Weber D, Banas B, Schulz C, Hamer O, et al.
Transplant Cell Ther
. 2023 Sep;
29(12):772.e1-772.e10.
PMID: 37777112
Chronic graft-versus-host disease (cGVHD) is the leading cause of late nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (alloHSCT) and defined by 8 diagnostic target organs. Recently, provisional criteria...
5.
Fante M, Harrer D, Zartner B, Luke F, Mayer S, Menhart K, et al.
Front Oncol
. 2023 Jun;
13:1177330.
PMID: 37305564
Purpose: Peripheral T-cell lymphoma (PTCL) is a rare and heterogenous hematologic malignancy with poor prognosis especially in elderly and frail patients who are not eligible for intensive treatment. The resulting...
6.
Stein-Thoeringer C, Saini N, Zamir E, Blumenberg V, Schubert M, Mor U, et al.
Nat Med
. 2023 Mar;
29(4):906-916.
PMID: 36914893
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the United States...
7.
Fante M, Felsenstein M, Mayer S, Gerken M, Klinkhammer-Schalke M, Herr W, et al.
Front Oncol
. 2022 May;
12:852987.
PMID: 35619924
Purpose: Treatment options in patients (pts.) with advanced relapsed and refractory aggressive B-cell lymphoma are limited. Palliative all-oral chemotherapy regimens reduce in-patient visits and contribute to quality of life. The...
8.
Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al.
Blood
. 2022 Mar;
140(4):349-358.
PMID: 35316325
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Here, we report the first German...
9.
Fante M, Decking S, Bruss C, Schreml S, Siska P, Kreutz M, et al.
Int J Mol Sci
. 2021 Apr;
22(5).
PMID: 33808005
Heat-inactivation of sera is used to reduce possible disturbing effects of complement factors in cell-culture experiments, but it is controversially discussed whether this procedure is appropriate or could be neglected....
10.
Fante M, Holler B, Weber D, Angstwurm K, Bergler T, Holler E, et al.
Ann Hematol
. 2020 Jul;
99(9):2181-2190.
PMID: 32715339
We retrospectively analyzed the safety and efficacy of cyclophosphamide (cyclo) for salvage treatment of chronic graft-versus-host disease (cGvHD) and cGvHD-associated (glomerulo-)nephritis at our center between 01/2010 and 11/2019. We identified...